Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Clinical and biological significance of hepsin overexpression in breast cancer.

Xing P, Li JG, Jin F, Zhao TT, Liu Q, Dong HT, Wei XL.

J Investig Med. 2011 Jun;59(5):803-10. doi: 10.2310/JIM.0b013e31821451a1.

PMID:
21383634
3.

[Effect of down-regulation of Oct4 gene on biological characteristics of MDA-MB-231 breast cancer stem cells].

[No authors listed]

Zhonghua Zhong Liu Za Zhi. 2015 Apr;37(4):251-7. Chinese.

PMID:
26462888
4.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.

Breast Cancer Res. 2007;9(6):R76.

5.

Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.

Matsuo T, Nakamura K, Takamoto N, Kodama J, Hongo A, Abrzua F, Nasu Y, Kumon H, Hiramatsu Y.

Anticancer Res. 2008 Jan-Feb;28(1A):159-64.

6.

Tumor-suppressor activity of RRIG1 in breast cancer.

Zhang G, Brewster A, Guan B, Fan Z, Brown PH, Xu XC.

BMC Cancer. 2011 Jan 25;11:32. doi: 10.1186/1471-2407-11-32.

7.

Molecular characterization of the tumor-suppressive function of nischarin in breast cancer.

Baranwal S, Wang Y, Rathinam R, Lee J, Jin L, McGoey R, Pylayeva Y, Giancotti F, Blobe GC, Alahari SK.

J Natl Cancer Inst. 2011 Oct 19;103(20):1513-28. doi: 10.1093/jnci/djr350. Epub 2011 Sep 14.

8.

Clinical significance of human kallikrein 12 gene expression in gastric cancer.

Zhao EH, Shen ZY, Liu H, Jin X, Cao H.

World J Gastroenterol. 2012 Dec 7;18(45):6597-604. doi: 10.3748/wjg.v18.i45.6597.

9.

Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.

Xuan JA, Schneider D, Toy P, Lin R, Newton A, Zhu Y, Finster S, Vogel D, Mintzer B, Dinter H, Light D, Parry R, Polokoff M, Whitlow M, Wu Q, Parry G.

Cancer Res. 2006 Apr 1;66(7):3611-9.

10.

[Expression and clinical significance of LRP16 gene in human breast cancer].

Liao DX, Han WD, Zhao YL, Pu YD, Mu YM, Luo CH, Li XH.

Ai Zheng. 2006 Jul;25(7):866-70. Chinese.

PMID:
16831279
11.

Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.

Li W, Wang BE, Moran P, Lipari T, Ganesan R, Corpuz R, Ludlam MJ, Gogineni A, Koeppen H, Bunting S, Gao WQ, Kirchhofer D.

Cancer Res. 2009 Nov 1;69(21):8395-402. doi: 10.1158/0008-5472.CAN-09-1995. Epub 2009 Oct 20.

12.

Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.

Parr C, Sanders AJ, Davies G, Martin T, Lane J, Mason MD, Mansel RE, Jiang WG.

Clin Cancer Res. 2007 Jun 15;13(12):3568-76.

13.

Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer.

Yuan SS, Hou MF, Hsieh YC, Huang CY, Lee YC, Chen YJ, Lo S.

J Natl Cancer Inst. 2012 Oct 3;104(19):1485-502. doi: 10.1093/jnci/djs355. Epub 2012 Aug 22.

PMID:
22914783
14.

Diversin is overexpressed in breast cancer and accelerates cell proliferation and invasion.

Yu X, Wang M, Dong Q, Jin F.

PLoS One. 2014 May 23;9(5):e98591. doi: 10.1371/journal.pone.0098591. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e116045.

15.

Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.

Pelkonen M, Luostari K, Tengström M, Ahonen H, Berdel B, Kataja V, Soini Y, Kosma VM, Mannermaa A.

BMC Cancer. 2015 May 27;15:431. doi: 10.1186/s12885-015-1440-5.

16.

Vascular endothelial growth inhibitor affects the invasion, apoptosis and vascularisation in breast cancer cell line MDA-MB-231.

Gao Y, Ge Z, Zhang Z, Bai Z, Ma X, Wang Y.

Chin Med J (Engl). 2014;127(10):1947-53.

PMID:
24824261
17.

miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer.

Zhang J, Kong X, Li J, Luo Q, Li X, Shen L, Chen L, Fang L.

Oncol Rep. 2014 Mar;31(3):1357-63. doi: 10.3892/or.2013.2934. Epub 2013 Dec 19.

PMID:
24366472
18.

Function of RasGRP3 in the formation and progression of human breast cancer.

Nagy Z, Kovács I, Török M, Tóth D, Vereb G, Buzás K, Juhász I, Blumberg PM, Bíró T, Czifra G.

Mol Cancer. 2014 Apr 29;13:96. doi: 10.1186/1476-4598-13-96.

19.

Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.

Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J.

Clin Cancer Res. 2005 Jun 15;11(12):4357-64.

20.

Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion.

Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, Shen H, Zhu X.

J Exp Clin Cancer Res. 2010 Jul 10;29:92. doi: 10.1186/1756-9966-29-92.

Supplemental Content

Support Center